Crucell

Crucell's technology

Crucell's strong product portfolio is supported by a range of patented technologies. Our cutting-edge technology platforms enable the cost-effective discovery, development andproduction of a range of biopharmaceutical products, including innovative vaccines, therapeutic proteins and gene therapies. In therapeutic areas where Crucell does not plan to develop its ownproducts, these proprietary technologies may be licensed out to other biopharmaceutical manufacturers or research groups.
Five core proprietary technology platforms
Crucell has five core proprietarytechnology platforms:
1. PER.C6® technology
2. AdVac® technology
3. MAbstract® technology
4. STAR® technology
5. Virosome technology
|
1. PER.C6® technology is acomprehensive package of tools designed to facilitate the large-scale production of safe and affordable biopharmaceutical products, such as vaccines, monoclonal antibodies and gene therapy products.
Thistechnology offers major advantages over other platforms used for manufacturing biological products and is uniquely positioned to meet the key challenges in the industry. These include the need toproduce larger volumes of product more quickly and cost-effectively, while meeting increasingly stringent safety requirements.

2. AdVac® technology involves the development and manufacture of novelvectors (gene transport vehicles) made from adenoviruses (harmless cold viruses) that very rarely infect humans, such as AD35. Genetic material encoding for viruses, parasites or bacteria can beinserted into these vectors to make novel vaccines against a broad range of human pathogens, or the vectors can be used to make gene therapy products.

3. Crucell’s MAbstract® technology is a humanantibody-based phage display system, which facilitates the discovery of novel drug targets and the identification of human monoclonal antibodies against those targets. A phage (or ‘bacteriophage’) is a...